血管內(nèi)皮生長因子B(VEGFB)重組蛋白
Recombinant Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號RPA144Hu01
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預(yù)測分子量23.2kDa
- 實際分子量27kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Pro22~Ala207 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 97%
- 等電點8.2
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1008¥ 2520¥ 5040¥ 15120¥ 37800
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure . Gene Sequencing (extract)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA144Hu01 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA144Hu01 | 血管內(nèi)皮生長因子B(VEGFB)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA144Hu01 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | IHC |
| LAA144Hu71 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA144Hu81 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| MAA144Hu22 | 血管內(nèi)皮生長因子B(VEGFB)單克隆抗體 | WB; IHC; ICC; IP. |
| LAA144Hu82 | 血管內(nèi)皮生長因子B(VEGFB)單克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAA144Hu72 | 血管內(nèi)皮生長因子B(VEGFB)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA144Hu | 血管內(nèi)皮生長因子B(VEGFB)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA144Hu | 血管內(nèi)皮生長因子B(VEGFB)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction.[PubMed: 22459379] |
| Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study[pubmed:29099033] |
| Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell[10.1007/s40618-017-0677-z] |
| EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction[] |
| Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors[34164713] |